Chemicals

3,4-Dibenzyloxybenzaldehyde

We are 3,4-Dibenzyloxybenzaldehyde CAS:5447-02-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 5447-02-9

Product Name: 3,4-Dibenzyloxybenzaldehyde

Other Name:

3,4-bis(phenylmethoxy)benzaldehyde

3,4-Bis(benzyloxy)benzaldehyde

Density: 1.2±0.1 g/cm3

Boiling Point: 492.4±35.0 °C at 760 mmHg

Melting Point: 91-94 °C (dec.)(lit.)

Molecular Formula: C21H18O3

Molecular Weight: 318.366

Flash Point: 243.9±12.4 °C

Exact Mass: 318.125580

PSA: 35.53000

LogP: 4.92

Vapour Pressure: 0.0±1.2 mmHg at 25°C

Index of Refraction: 1.623

Specification

Appearance: Light yellow to yellow powder

Assay: ≥99.0%

Water: ≤0.50%

Application

Be used as pharmaceutical intermediate.

Package: 25kg/drum, can also be designed according to customer requirements.

Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

3,4-Dibenzyloxybenzaldehyde

Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.6-Hydroxy-2(1H)-3,4-dihydroquinolinone China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.540-63-6 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).2-tiofenotiol CAS:7774-74-5 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.

Product Name
4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsufonyl)amino]pyrimidine-5-yl-methanol	View Details
7-Chloro-8-Methylquinoline	View Details
1-(3-ethylpyrazin-2-yl)ethanone	View Details